US EditionUltrasensitive Liquid Biopsy Affective in Predicting and Monitoring Immunotherapy Response, Study Shows
2 Articles
2 Articles
Ultrasensitive liquid biopsy affective in predicting and monitoring immunotherapy response, study shows
Published today in Clinical Cancer Research, findings from a study led by investigators at the Vall d'Hebron Institute of Oncology (VHIO), which forms part of the Vall d'Hebron Campus, underscore the efficacy of analyzing circulating tumor DNA (ctDNA) using a highly sensitive liquid biopsy platform for evaluating early response, predicting survival and tumor progression in patients with advanced cancers who received treatment with immunotherapy …
These are the first results presented by IMMUNOMICS-VHIO, a project-platform for the discovery and validation of biomarkers for immunotherapy that is part of the Comprehensive Program of Immunotherapy and Immunology of Cancer (CAIMI) of VHIO, funded by the BBVA Foundation. Dr Rodrigo Toledo’s laboratory is also funded by the FERO Foundation and for this study has benefited from the collaboration of the project PREDICT (Personalized Response Imag…
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
